Navigation Links
Clinical Results for Oramed's Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
Date:5/1/2013

ection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com.

The company's fact sheet, the content of which is not part of this press release, can be viewed here.

Forward-looking statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements when we discuss the potential of ORMD-0810 as a treatment that can considerably aid a patient population resistant to standard anti-diabetes treatment protocols or our oral insulin and oral exenatide candidates approaching Phase 2 clinical trials and 2a clinical trials, respectively. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trial
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
2. Rush University Medical Center Presents Positive MuGard Clinical Data at the Oncology Nursing Society 38th Annual Congress
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
5. Elekta to Highlight Clinical and Safety Advantages of Gamma Knife Radiosurgery at 2013 AANS Meeting
6. Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
7. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
8. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
9. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
10. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
11. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... YORK , Sept. 29, 2014 EU5 ... Summary GlobalData,s new report, "EU5 Capsule ... data on the EU5 Capsule Endoscopy Systems market. The ... (in units) and average prices (in US dollars) within ... and Capsule Endoscopy Workstations. The report also ...
(Date:9/29/2014)... Pharmaceutical Care Management Association (PCMA) President and ... that could reduce prescription fraud and abuse in Medicare ... Opioid Abuse: Fighting Back on Many Fronts ," sponsored ... The briefing featured several government and industry ... fraud. The Centers for Disease Control and Prevention has ...
(Date:9/29/2014)... LAKE CITY , Sept. 29, 2014 /PRNewswire/ ... has scheduled a conference call for investors today ... for the quarter and year ended June 30, ... in participating is (800) 771-7941. Dynatronics ... soft goods and supplies, treatment tables and rehabilitation ...
Breaking Medicine Technology:EU5 Capsule Endoscopy Systems Market Outlook to 2020 2EU5 Capsule Endoscopy Systems Market Outlook to 2020 3PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2
... Percutaneous Administration (CUPID) Data Highlight Safety Profile and ... 26 Celladon Corporation today announced that results ... advanced heart failure, including Phase 1/2 data of ... Zsebo, PhD, President and CEO, Celladon Corporation and ...
... 26 Senesco Technologies, Inc. ("Senesco" or the "Company") ... mouse influenza survival studies that were conducted in Dr. William Scheld,s ... Mice treated with an siRNA against Senesco,s Factor 5A gene ... rate for mice that received no treatment or a control siRNA.A ...
Cached Medicine Technology:Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 3
(Date:9/30/2014)... Dennis Thompson HealthDay Reporter ... day, people receive medical implants -- artificial valves, hip ... have been rigorously tested before or after their approval by ... The studies -- conducted by prominent nonprofit groups and ... -- lay the blame for inadequate medical device testing on ...
(Date:9/30/2014)... 30, 2014 Houstonians seeking the latest ... to visit on the Internet. Paul Vitenas, JR. ... respected cosmetic surgeons, has launched a new website to ... of Botox Cosmetic services. The new website ... According to the new website, Botox Cosmetic is a ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Neuromuscular ... people throughout the United States and worldwide. It ... Disease are diagnosed each year, adding to the ... the disease. Approximately 400,000 people in the US ... worldwide. Add to these statistics the 2.4 percent ...
(Date:9/30/2014)... Gummy teeth treatment expert, ... for dark gums. Dark gums are usually considered a ... self-conscious about their smiles. Dr. Farnoosh has pioneered a ... one of the few dental professionals nationwide offering black ... business leaders, high-ranking officials and patients from all over ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Herceptin is the best ... HER2-positive and should remain the standard of care for ... a long-term clinical trial. HER2-positive breast cancers tend ... cancer, according to the Mayo Clinic. For the ... either Herceptin (trastuzumab) or Tykerb (lapatinib) in addition to ...
Breaking Medicine News(10 mins):Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2
... (CLP) at Thomas Jefferson University Hospital, recently received an ... scope of the normal duties of serving as ... American College of Surgeons Commission on Cancer (CoC). ... appointment and is among a national network of over ...
... ... Use Dashboard will provide a single location where an organization can see, at a ... ... 2010 -- Health Care DataWorks , a Technology Company created to commercialize the ...
... finds they are equal to artery-clearing surgery, but another ... -- Both stents and conventional surgery appear to be ... arteries are blocked, according to research presented Friday at ... , However, a second stents-versus-surgery trial, published Thursday in ...
... ... company, has signed a strategic partnership agreement with Medical Insight to complete the ... capability across the healthcare enterprise. , , ... Milwaukee (PRWEB) February 26, 2010 -- ...
... The natural-occurring biopolymer known as chitosan is being put ... the diet of ruminants, according to research carried out ... presence of these antibiotics as additives in the diet ... since 2006, given that their use is linked to ...
... ... ... ... ...
Cached Medicine News:Health News:Jefferson surgeon receives outstanding performance award from American College Of Surgeons 2Health News:HCD Announces Meaningful Use Dashboard for Health Systems 2Health News:Stents May Be Effective Weapon Against Stroke 2Health News:Stents May Be Effective Weapon Against Stroke 3Health News:Stents May Be Effective Weapon Against Stroke 4Health News:TeraMedica Inks Reseller Agreement With Medical Insight Enterprise Image Viewer Company 2Health News:TeraMedica Inks Reseller Agreement With Medical Insight Enterprise Image Viewer Company 3Health News:Chitosan as alternative to growth-promoting antibiotics for ruminants 2Health News:Chitosan as alternative to growth-promoting antibiotics for ruminants 3Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 2Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 3Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 4Health News:Dairy Industry Raises a Glass of Milk to Let's Move! Campaign 5
Manufactured with large, shatter-resistant Clear Pb leaded acrylic panels which provide a wide field of vision for one or more users. Opaque lower panels are covered in your choice of decorative viny...
... Excellent for patient protection ... erect chest and cervical spine. ... 0.5mm shield. Height adjustable 36" ... sturdy star-leg aluminum base for ...
RayShield Frame Mounted Overhead Lead Acrylic Barriers are offered in a choice of three sizes: 60 cm x 80 cm ( 24" x 32") wide, 60 cm x 50 cm( 24" x 20") wide. Lead acrylic windows of 0.5 mm and 1.0 ...
Ball-and-socket center mount can rotate 360, allowing them to be turned hoirzontally, vertically, or at any angle. Very versatile! Available with or without torso placement contour cutout and in thre...
Medicine Products: